Thymosin Beta 4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myelomaCaers, Jo ; ; et alin Haematologica (2010), 95(1), 163-167 Detailed reference viewed: 13 (1 ULg) Unraveling the biology of MM disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.Caers, Jo ; ; et alin Bulletin du Cancer (2008), 95(3), 301-13 Detailed reference viewed: 4 (0 ULg) Antitumor and anti-angiogenic effects of aplidin in the 5T33MM model, syngeneic model of multiple myelomaCaers, Jo ; ; et alin British Journal of Cancer (2008), 98(12), 1966-74 Detailed reference viewed: 9 (0 ULg) Multiple Myeloma, an update on diagnosis and treatment.Caers, Jo ; ; et alin European Journal of Haematology (2008), 81(5), 329-343 Detailed reference viewed: 5 (3 ULg) Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.; ; et al in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2006), 20(10), 1870-9 Detailed reference viewed: 6 (2 ULg) The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM modelCaers, Jo ; ; et alin British Journal of Haematology (2006), 132((4)), 469-77 Detailed reference viewed: 2 (0 ULg) Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports.Caers, Jo ; ; et alin Supportive Care in Cancer (2005), 13((5)), 325-31 Detailed reference viewed: 14 (0 ULg) Of mice and men: disease models of multiple myelomaCaers, Jo ; ; et alin Drugs Discovery Today: disease models (2005), 1(4), 373-380 Detailed reference viewed: 15 (1 ULg) Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model; ; et al in American Journal of Pathology (2004), 165(3), 869-878 Matrix metalloproteinases (MMPs) are known to play a role in cell growth, invasion, angiogenesis, metastasis, and bone degradation, all important events in the pathogenesis of cancer. Multiple myeloma is ... [more ▼] Matrix metalloproteinases (MMPs) are known to play a role in cell growth, invasion, angiogenesis, metastasis, and bone degradation, all important events in the pathogenesis of cancer. Multiple myeloma is a B-cell cancer characterized by the proliferation of malignant plasma cells in the bone marrow, increased angiogenesis, and the development of osteolytic bone disease. The role of MMPs in the development of multiple myeloma is poorly understood. Using SC-964, a potent inhibitor of several MMPs (MMP-2, -3, -8, -9, and -13), we investigated the role of MMPs in the 5T2MM murine model. Reverse transcriptase-polymerase chain reaction demonstrated the presence of mRNA for MMP-2, -8, -9, and -13 in 5T2MM-diseased bone marrow. Mice bearing 5T2MM cells were given access to food containing SC-964. The concentration of SC-964 measured in the plasma of mice after 11 days of treatment was able to inhibit MMP-9 activity in gelatin zymography. Treatment of 5T2MM-bearing mice resulted in a significant reduction in tumor burden, a significant decrease in angiogenesis, and partially protective effect against the development of osteolytic bone disease. The direct role of MMPs in these different processes was confirmed by in vitro experiments. All these results support the multifunctional role of MMPs in the development of multiple myeloma. [less ▲] Detailed reference viewed: 18 (1 ULg) |
||